Search
Search Results
##search.searchResults.foundPlural##
-
Hsa-miR-5581-3p and hsa-miR-542-3p target the F8 gene in hemophilia A without F8 mutations F8 gene is regulated by miRNAs
1122PDF: 492HTML: 235 -
NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?
3257PDF: 1709HTML: 1086 -
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
2037PDF: 826HTML: 247 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1379HTML: 438PDF: 822 -
GROUP-BASED TRAJECTORY MODELING OF PLATELET IN PATIENTS WITH APLASTIC ANEMIA: A STUDY BASED ON THE MIMIC DATABASE
1005PDF: 995Suppl. Files: 636HTML: 139 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1533PDF: 946HTML: 223 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1730PDF: 1166HTML: 246 -
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
4767PDF: 2838HTML: 2288 -
CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA
2610PDF: 1611HTML: 2355Table1: 190 -
OUTCOME OF ANTIFUNGAL COMBINATION THERAPY FOR INVASIVE MOLD INFECTIONS IN HEMATOLOGICAL PATIENTS IS INDEPENDENT OF THE CHOSEN COMBINATION
1106PDF: 544HTML: 1690Figures: 167Fifures Sanz: 176tables Sanz: 180Untitled: 176 -
ClinicaI Reversible Myelopathy in T-Cell Lymphoblastic Lymphoma Treated with Nelarabine and Radiotherapy: Report of a Case and Review of Literature of an Increasing Complication
2378PDF: 998HTML: 1648Fig 1: 185Tab I: 213Cover Letter: 205 -
Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and granulocyte-colony stimulating factor with subsequent bridging to myeloablative allogeneic hematopoietic stem cell transplantation Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and G-CSF
1765PDF: 573HTML: 283 -
COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS COVID-19 IN CHILDREN AND ADOLESCENT.
2406PDF: 937HTML: 302 -
CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS CAR-T and Follicular Lymphoma
2283PDF: 1825HTML: 144 -
CORD BLOOD PLATELET LYSATE: IN VITRO EVALUATION TO SUPPORT THE USE IN REGENERATIVE MEDICINE. Cord and adult blood platelet lysates
1954PDF: 1135HTML: 251 -
GASTROINTESTINAL MYELOID SARCOMA A CASE PRESENTATION AND CRITICAL REVIEW OF THE LITERATURE GASTROINTESTINAL MYELOID SARCOMA
1316PDF: 614HTML: 241 -
WHAT ARE FUNGAL INFECTIONS?
4193PDF: 2385HTML: 27615de Pauw: 235 -
T-LYMPHOCYTES EXPRESSION OF TOLL-LIKE RECEPTORS 2 AND 4 IN ACUTE MYELOID LEUKEMIA PATIENTS WITH INVASIVE FUNGAL INFECTIONS Toll-like receptors 2 and 4 in Acute Myeloid Leukemia Patients with Invasive Fungal Infections
1779PDF: 703HTML: 369 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7519PDF: 2422HTML: 1733Table 1.: 208Table 2.: 217Table 3.: 202Table 4.: 200 -
Bordetella Bronchiseptica in the Immunosuppressed Population – A Case Series and Review.
2454PDF: 1303HTML: 1751CoverLetter: 183 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2806PDF: 1009HTML: 5520 -
Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure Memory Cell Population Of Natural Killer Cells in COVID-19 and Cytomegalovirus Exposure
1170PDF: 917HTML: 289 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
9076PDF: 6061HTML: 87959Fig.1b: 185Fig.1c: 190Fig.2a: 177Fig.2b: 177Fig.4: 188Fig.2c: 185Fig.3: 182Tab.1: 228Tab.2: 207Tab.3: 190Tab.4: 222Fig1a: 186 -
OLDER ADULTS WITH PH NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA: A MONOCENTRIC EXPERIENCE ON CONSECUTIVE PATIENTS AGED MORE THAN 55 YEARS Older Adults with Ph Negative Acute Lymphoblastic Leukemia
1307PDF: 569Suppl. Files: 346HTML: 145 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1247PDF: 998HTML: 211







